[Featured Stock] T&R Biofab Shows Technological Superiority Over 3 Trillion Cellink... Smooth Joint Development with J&J

[Asia Economy Reporter Hyungsoo Park] The stock price of T&R Biofab continues to show strong momentum. Recently, as 3D printing technology that utilizes not only extracellular matrix (ECM) but also cell technology to create organoids or actual biological organs has gained attention, there is an ongoing movement to re-evaluate the corporate value of T&R Biofab.

As of 11:50 AM on the 23rd, T&R Biofab is trading at 38,950 KRW, up 27.29% from the previous day.

Since the beginning of this month, the stock price has drawn a steep upward curve, pushing the market capitalization beyond 300 billion KRW.

Byung-guk Park, a researcher at NH Investment & Securities, stated in a recent report, "Cellink (CLLKF.US), which is co-developing with AstraZeneca since 2020, operates a business similar to T&R Biofab," adding, "Unlike Cellink, T&R Biofab has secured and utilizes its own induced pluripotent stem cell (iPSC) differentiation technology, representing a more advanced level."

He continued, "Cellink's stock price rose more than 500% from early 2020," and "it formed a market capitalization of 3 trillion KRW."

Cellink's market capitalization steadily grew from around 600 billion KRW in early 2020. Joint development projects with global pharmaceutical companies such as AstraZeneca acted as catalysts for the stock price increase.

Researcher Park emphasized, "The 3D scaffold joint development contract with J&J Ethicon, signed in February last year, will be completed in June this year," and "based on the initial results, specific development and contracts for commercialization are expected to proceed."

He analyzed, "The pipeline under development is a biological ECM scaffold inserted between the skin and implant during breast reconstruction surgery," and "currently, artificial dermis from cadavers is being obtained and used."

The 3D printing market in the medical field is projected to reach 3.7 billion USD by 2026. Researcher Park said, "T&R Biofab possesses top-tier technology, including the world's third-largest number of 3D printing patents, the first dECM cell printing technology, and proprietary iPSC differentiation technology," and assessed, "The area where it lagged behind Cellink was marketing capability."

He added, "For technologically excellent T&R Biofab to be properly evaluated, it is urgent to develop business development (BD) capabilities alongside research and development to achieve results in global partnerships."

This content was produced with the assistance of AI translation services.